Anebulo Pharmaceuticals Inc

NASDAQ ANEB

Download Data

Anebulo Pharmaceuticals Inc Return on Total Capital (ROTC) for the Trailing 12 Months (TTM) ending March 31, 2024

Anebulo Pharmaceuticals Inc Return on Total Capital (ROTC) is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Return on total capital measures the profitability of a company relative to its total capital, which includes total debt and shareholders' equity. It is calculated by dividing the net income by the sum of total debt and shareholders' equity. This ratio provides insights into the return generated for each unit of total capital invested in the company. A higher return on total capital indicates better profitability and efficient utilization of both debt and equity capital.
NASDAQ: ANEB

Anebulo Pharmaceuticals Inc

CEO Dr. Joseph F. Lawler M.D., Ph.D.
IPO Date May 7, 2021
Location United States
Headquarters 1415 Ranch Road 620 South, Lakeway, TX, United States, 78734
Employees 2
Sector Healthcare
Industry Biotechnology
Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email